Mission & Vision
Our mission is to develop novel biological drugs and personalized therapies to address unmet challenges in human diseases providing innovative solutions based on the microbiota. We are a preclinical stage company developing novel biological drugs, based on commensal bacteria, targeting infectious diseases. Our lead candidate, MVT-201, is an orally administered capsule generated under cGMP conditions that represents the complete microbiota ecosystem and will enter clinical trials in Q4 2023.
Microviable´s PharmaBiota® platform enabled the creation of a large and diverse bacterial strain collection with thousands of isolates to generate a second category of biological products based on our fully integrated R&D capabilities. With another 4 preclinical programs ongoing, we are leveraging the microbiota to improve the patients´ quality of life. In addition to our internal programs, Microviable has an established partnership with Inmunomet Intolerancias y Disbiosis to develop microbiota therapies as personalized medicine.
You can follow the latest news of MicroViable in this section
Microviable Therapeutics appoints Luis Gosálbez as a member of its Business Advisory Board
Microviable Therapeutics announced the appointment of Dr. Luis Gosálbez as a member of its Business [...]
Microviable Therapeutics will be presenting at XIV Workshop of SEMiPYP
Microviable Therapeutics will be presenting at XIV Workshop of SEMiPYP (Spanish Society of Microbiota, Probiotics [...]
Microviable will be attending the XIV Workshop of the SEMiPyP
Microviable Therapeutics will be attending the XIV Workshop of SEMiPYP (Spanish Society of Microbiota, Probiotics [...]
Get in touch with us for any questions using the following contact form.